This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Radiofrequency Ablation During Surgery in Treating Patients With Non-Small Cell Lung Cancer

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
Fox Chase Cancer Center Identifier:
First received: June 6, 2002
Last updated: February 11, 2010
Last verified: February 2010

RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. Combining radiofrequency ablation with surgery may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining radiofrequency ablation with surgery in treating patients who have stage I or stage II non-small cell lung cancer.

Condition Intervention Phase
Lung Cancer Procedure: conventional surgery Procedure: radiofrequency ablation Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Pilot Study: Radiofrequency Ablation Of Resectable Non-Small Cell Lung Cancer

Resource links provided by NLM:

Further study details as provided by Fox Chase Cancer Center:

Study Start Date: June 2002
Study Completion Date: February 2004
Detailed Description:


  • Determine the acute effects of intraoperative radiofrequency tumor ablation (RFA) in patients with resectable non-small cell lung cancer.
  • Determine the treatment-related toxicity in patients treated with this therapy.
  • Determine the dimensions of the RFA lesion produced by the ablation procedure in these patients.

OUTLINE: Patients undergo intraoperative radiofrequency tumor ablation over 10-15 minutes for each tumor immediately followed by tumor resection.

PROJECTED ACCRUAL: A maximum of 20 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of malignant non-small cell lung cancer (NSCLC)

    • Intraoperative needle biopsy confirmation allowed
  • Resectable disease (stage I or II)
  • All tissue to be treated by radiofrequency tumor ablation must be completely contained within boundaries of planned lung resection
  • Medically fit to undergo lung resection



  • Over 18

Performance status:

  • Not specified

Life expectancy:

  • Not specified


  • Not specified


  • Not specified


  • Not specified


  • Not pregnant or nursing


Biologic therapy:

  • No prior or concurrent biologic therapy


  • No prior or concurrent chemotherapy

Endocrine therapy:

  • No prior or concurrent endocrine therapy


  • No prior or concurrent radiotherapy


  • See Disease Characteristics


  • No other prior therapy for NSCLC
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00039507

United States, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
Sponsors and Collaborators
Fox Chase Cancer Center
National Cancer Institute (NCI)
Study Chair: Walter J. Scott, MD, FACS Fox Chase Cancer Center
  More Information Identifier: NCT00039507     History of Changes
Other Study ID Numbers: CDR0000069389
P30CA006927 ( U.S. NIH Grant/Contract )
Study First Received: June 6, 2002
Last Updated: February 11, 2010

Keywords provided by Fox Chase Cancer Center:
stage I non-small cell lung cancer
stage II non-small cell lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms processed this record on August 22, 2017